Navigation Links
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Date:10/12/2009

ROCKVILLE, Md., Oct. 12 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

The Phase 1 SBIR grant will support studies with SQ641 to investigate activity against several different Mycobacterium avium complex and Mycobacterium abscessus strains in white blood cells in vitro and in animal models. These studies will measure SQ641 activity against clinically important NTM pathogens in anticipation of potential advancement to Investigational New Drug (IND)-directed preclinical studies.

"There are few effective drugs currently available to treat NTM-related infections," said Dr. Carol Nacy, CEO of Sequella, "and these infections are increasing dramatically in the U.S., nearly 5% per year from 1998 to 2007. New infections were reported not only in immunocompromised individuals, as has been seen in the past, but also in a significant and rising number of patients with intact immune systems. New and more potent drugs will be required to treat these bacteria, ubiquitous in water and soil, as they are now posing a threat to everyone."

About SQ641

SQ641 is the lead drug candidate from a 7000-compound library of semi-synthetic translocase 1 (TL-1) inhibitors developed as potential treatments for mycobacterial diseases or bacterial pneumonia (Streptococcus pneumoniae). TL-1 is a unique antibacterial target, an enzyme required for cell wall synthesis in all bacteria. SQ641 possesses exceptional activity against all members of the Mycobacteria family of bacteri
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
2. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
3. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
4. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
5. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
6. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
7. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
8. Sinovac Obtains Production License for H1N1 Vaccine
9. Blackrock Microsystems Obtains Expanded 510(k) to Market NeuroPort System
10. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
11. NeoStem Obtains Exclusive License to Innovative Stem Cell Procedure Treating Musculoskeletal Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  The Chicago Bears are excited to announce the ... in an effort to raise awareness of skin cancer. ... SPOT me™ skin cancer screenings at a preseason fan ... SPOT me™ is an educational campaign designed to inform ... of skin cancer, and encourages people to get screened ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
(Date:7/30/2014)... Yuma, AZ (PRWEB) July 30, 2014 ... , State-of-the-art facility and complementary therapies brings comprehensive ... square foot, state-of-the-art Yuma Regional Cancer Center has ... since 2012, the program includes services such as ... laboratory, massage therapy, American Cancer Society Resource Center, ...
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
Breaking Biology Technology:Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... (Nasdaq: BNVI ) today announced financial ... "Scientific development, regulatory progress and growth accurately characterize ... chairman and chief executive officer. "We successfully laid ... is essential for the successful approval and marketing ...
... Corporation (NYSE: SGP ) is scheduled to ... first quarter on Tuesday, April 21, 2009. At ... a conference call to review results for the 2009 ... and other members of management will host the conference ...
... LLC, and Burrill & Company Collaborating on Strategic ... 12 Developer Tower Investments, LLC ("Tower"), and ... ("Burrill") today announced a formal partnership with aims ... planned development and funding related to the "shovel-ready" ...
Cached Biology Technology:Bionovo Announces 2008 Highlights and Year-End Financial Results 2Bionovo Announces 2008 Highlights and Year-End Financial Results 3Bionovo Announces 2008 Highlights and Year-End Financial Results 4Bionovo Announces 2008 Highlights and Year-End Financial Results 5Bionovo Announces 2008 Highlights and Year-End Financial Results 6Bionovo Announces 2008 Highlights and Year-End Financial Results 7Bionovo Announces 2008 Highlights and Year-End Financial Results 8Bionovo Announces 2008 Highlights and Year-End Financial Results 9Bionovo Announces 2008 Highlights and Year-End Financial Results 10Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... 3,000 pieces is still in its infant stage. But ... of major significance. "Amazingly often, we are findingin addition ... that we found in Baltic amber," explained Bonn paleontologist ... comes from the Baltic Sea region, which is almost ... e.g., the coastal regions of Mecklenburg, Poland and Belarus. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... stress a typical married couple feels during an ordinary half-hour ... from wounds by at least one day, a new study ... routinely hostile toward each other, the delay in that healing ... have major financial implications for medical centers and health care ...
... an AIDS vaccine, UCLA AIDS Institute researchers report the ... the infection in different ways. , Detailed in the ... ( http://jvi.asm.org ), the findings show that the body's ... determined. , The researchers followed the cases of male ...
... much more sophisticated visual system than previously thought, according ... which bees were able to solve complicated colour puzzles. ... of the most difficult challenges of vision - namely, ... by suggesting that bees solve this problem using their ...
Cached Biology News:Stress substantially slows human body's ability to heal 2Stress substantially slows human body's ability to heal 3UCLA scientists discover immune response to HIV differs, even in identical twins 2Bees solve complex colour puzzles 2